Cargando…

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

OBJECTIVES: Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobrota, Rucsandra, Maurer, Britta, Graf, Nicole, Jordan, Suzana, Mihai, Carina, Kowal-Bielecka, Otylia, Allanore, Yannick, Distler, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036205/ https://www.ncbi.nlm.nih.gov/pubmed/27016052 http://dx.doi.org/10.1136/annrheumdis-2015-208024

Ejemplares similares

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis
por: Evers, Caroline, et al.
Publicado: (2021)

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis
por: Zampatti, Norina, et al.
Publicado: (2021)

ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis
por: Bütikofer, Lukas, et al.
Publicado: (2020)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database
por: Allanore, Yannick, et al.
Publicado: (2020)

Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
por: Mihai, Carina, et al.
Publicado: (2020)

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study
por: Jaeger, Veronika K., et al.
Publicado: (2016)

Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population
por: Hachulla, Eric, et al.
Publicado: (2015)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Regulation of eicosanoid production in peripheral blood mononuclear cells from patients with systemic sclerosis
por: Kowal-Bielecka, Otylia, et al.
Publicado: (2007)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
por: Blagojevic, J., et al.
Publicado: (2019)

Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China
por: Hu, Shasha, et al.
Publicado: (2018)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

Comparison of hyaluronic acid in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus
por: Cylwik, Bogdan, et al.
Publicado: (2021)

Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis
por: Nagy, Gabriella, et al.
Publicado: (2023)

Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
por: Moinzadeh, Pia, et al.
Publicado: (2015)

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
por: Herrick, Ariane L, et al.
Publicado: (2017)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Volumetric Cone Beam Computed Tomography for the Assessment of Oral Manifestations in Systemic Sclerosis: Data from an EUSTAR Cohort
por: Iordache, Cristina, et al.
Publicado: (2019)

Purtscher-like Retinopathy in a Patient with Systemic Sclerosis: A Case Report and Narrative Review
por: Pieklarz, Barbara, et al.
Publicado: (2023)

Peripapillary choroidal vascularity index and thickness in patients with systemic sclerosis
por: Pieklarz, Barbara, et al.
Publicado: (2023)

Expression of LIGHT/TNFSF14 and Its Receptors, HVEM and LTβR, Correlates with the Severity of Fibrosis in Lacrimal Sacs from Patients with Lacrimal Duct Obstruction
por: Bielecki, Pawel, et al.
Publicado: (2020)

High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis
por: Kowal-Bielecka, Otylia, et al.
Publicado: (2013)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

The enigma of mixed connective tissue disease—challenges in routine care
por: Wanzenried, Adrian, et al.
Publicado: (2022)

Diagnostic Power of Galectin-3 in Rheumatic Diseases
por: Gruszewska, Ewa, et al.
Publicado: (2020)

Vision transformer assisting rheumatologists in screening for capillaroscopy changes in systemic sclerosis: an artificial intelligence model
por: Garaiman, Alexandru, et al.
Publicado: (2022)

Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries
por: Stamm, Tanja A, et al.
Publicado: (2011)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
por: Meier, C., et al.
Publicado: (2020)

Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study
por: Walker, Ulrich A., et al.
Publicado: (2018)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis
por: Müller, Bettina, et al.
Publicado: (2020)

Results of Florida's Amyotrophic Lateral Sclerosis Surveillance Project, 2009–2011
por: Freer, Cecilia, et al.
Publicado: (2015)

Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States
por: Rechtman, Lindsay, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o4ale10pg55lfoarao6ffovu6c